These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 9233591)
1. Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide. McQuaker IG; Haynes AP; Stainer C; Anderson S; Russell NH Br J Haematol; 1997 Jul; 98(1):228-33. PubMed ID: 9233591 [TBL] [Abstract][Full Text] [Related]
2. Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease. McQuaker I; Haynes A; Stainer C; Byrne J; Russell N Bone Marrow Transplant; 1999 Oct; 24(7):715-22. PubMed ID: 10516673 [TBL] [Abstract][Full Text] [Related]
3. Dose-Modified Ifosfamide, Epirubicin, and Etoposide is a Safe and Effective Salvage Therapy with High Peripheral Blood Stem Cell Mobilization Capacity for Poorly Mobilized Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients. Fukunaga A; Hyuga M; Iwasaki M; Nakae Y; Kishimoto W; Maesako Y; Arima N J Clin Exp Hematop; 2016; 56(1):50-4. PubMed ID: 27334858 [TBL] [Abstract][Full Text] [Related]
4. Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization. Reiser M; Josting A; Draube A; Mapara MY; Scheid C; Chemnitz J; Tesch H; Wolf J; Diehl V; Söhngen D; Engert A Bone Marrow Transplant; 1999 Jun; 23(12):1223-8. PubMed ID: 10414907 [TBL] [Abstract][Full Text] [Related]
5. IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosphamide, carboplatin and etoposide) in the context of salvage therapy for lymphoma. Fox CP; McMillan AK; Bishton MJ; Haynes AP; Russell NH Br J Haematol; 2008 Apr; 141(2):244-8. PubMed ID: 18353164 [TBL] [Abstract][Full Text] [Related]
6. Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients. Nowrousian MR; Waschke S; Bojko P; Welt A; Schuett P; Ebeling P; Flasshove M; Moritz T; Schuette J; Seeber S Ann Oncol; 2003; 14 Suppl 1():i29-36. PubMed ID: 12736228 [TBL] [Abstract][Full Text] [Related]
7. Clonogenic potential and phenotypic analysis of CD34+ cells mobilized by different chemotherapy regimens. Cesana C; Regazzi E; Garau D; Caramatti C; Mangoni L; Rizzoli V Haematologica; 1999 Sep; 84(9):771-8. PubMed ID: 10477448 [TBL] [Abstract][Full Text] [Related]
8. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Demirer T; Buckner CD; Gooley T; Appelbaum FR; Rowley S; Chauncey T; Lilleby K; Storb R; Bensinger WI Bone Marrow Transplant; 1996 Jun; 17(6):937-41. PubMed ID: 8807097 [TBL] [Abstract][Full Text] [Related]
9. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. Watts MJ; Sullivan AM; Jamieson E; Pearce R; Fielding A; Devereux S; Goldstone AH; Linch DC J Clin Oncol; 1997 Feb; 15(2):535-46. PubMed ID: 9053475 [TBL] [Abstract][Full Text] [Related]
10. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622 [TBL] [Abstract][Full Text] [Related]
11. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF. Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898 [TBL] [Abstract][Full Text] [Related]
12. Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation. Xia W; Ma CK; Reid C; Bai L; Wong K; Kerridge I; Ward C; Greenwood M J Clin Apher; 2014 Dec; 29(6):322-30. PubMed ID: 24944079 [TBL] [Abstract][Full Text] [Related]
13. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609 [TBL] [Abstract][Full Text] [Related]
14. ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients. Watts MJ; Ings SJ; Leverett D; MacMillan A; Devereux S; Goldstone AH; Linch DC Br J Cancer; 2000 Jan; 82(2):278-82. PubMed ID: 10646877 [TBL] [Abstract][Full Text] [Related]
15. High-dose etoposide plus granulocyte colony-stimulating factor as an effective chemomobilization regimen for autologous stem cell transplantation in patients with non-Hodgkin Lymphoma previously treated with CHOP-based chemotherapy: a study from the Consortium for Improving Survival of Lymphoma. Hyun SY; Cheong JW; Kim SJ; Min YH; Yang DH; Ahn JS; Lee WS; Ryoo HM; Do YR; Lee HS; Lee JH; Oh SY; Suh C; Yhim HY; Kim JS Biol Blood Marrow Transplant; 2014 Jan; 20(1):73-9. PubMed ID: 24141009 [TBL] [Abstract][Full Text] [Related]
16. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. Schwartzberg LS; Birch R; Hazelton B; Tauer KW; Lee P; Altemose R; George C; Blanco R; Wittlin F; Cohen J J Hematother; 1992; 1(4):317-27. PubMed ID: 1285381 [TBL] [Abstract][Full Text] [Related]
17. Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. Bishton MJ; Lush RJ; Byrne JL; Russell NH; Shaw BE; Haynes AP Br J Haematol; 2007 Mar; 136(5):752-61. PubMed ID: 17313378 [TBL] [Abstract][Full Text] [Related]
18. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF]. Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou SY; Zhou AP; Zhang CG; Ai B Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058 [TBL] [Abstract][Full Text] [Related]
19. Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells. Vogel W; Kunert C; Blumenstengel K; Fricke HJ; Kath R; Sayer HG; Höffken K J Cancer Res Clin Oncol; 1998; 124(6):341-5. PubMed ID: 9692843 [TBL] [Abstract][Full Text] [Related]
20. Mobilization of peripheral blood progenitor cells in patients with breast cancer: a prospective randomized trial comparing rhG-CSF with the combination of rhG-CSF plus rhEpo after VIP-E chemotherapy. Waller CF; von Lintig F; Daskalakis A; Musahl V; Lange W Bone Marrow Transplant; 1999 Jul; 24(1):19-24. PubMed ID: 10435729 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]